---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138934"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:52:17.059535+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics reports Q1 2023 net loss of $10.2M; IND cleared for SNS-101 Phase 1/2 trial

## Summary
- Cash, cash equivalents and marketable securities were $95.5M as of March 31, 2023; cash runway into H2 2025.
- Net loss was $10.2M for Q1 2023, compared to $12.4M for Q1 2022; R&D expenses decreased to $5.2M.
- FDA cleared IND for SNS-101 (conditionally active anti-VISTA antibody); Phase 1/2 trial enrollment and dosing expected mid-2023.
- CRADA signed with NCI for VISTA research; SNS-102 and SNS-103 candidate selection on track for 2023.

## SEC filing metadata
- accession: 0001193125-23-138934
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/0001193125-23-138934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/d456403d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138934
- JSON: https://secwatch.observer/filing/0001193125-23-138934.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138934.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $10.2 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $10.2 million
  - Result: reported results
  source text: Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2023, and provided recent business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/0001193125-23-138934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.